Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2516 crossover study on postprandial reflux episodes in healthy male volunteers
NL-OMON34821Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing AZD2516 with Placebo (2 arms). Primary endpoint: Number of reflux episodes. Planned start Jun 2010; status: not yet recruiting.
02
Drugs
AZD2516
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NL-OMON34821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34821.